Early diagnosis of systemic scleroderma

Czech version

Authors: Adéla Skoumalová ¹; Pavel Horák ¹; Zuzana Heřmanová ²; Jakub Videman ¹; Andrea Smržová ¹; Viktor Palla ³
Authors‘ workplace: III. interní klinika – nefrologická, revmatologická a endokrinologická, FN a LF UP Olomouc ¹; Ústav imunologie, FN a LF UP Olomouc ²; Klinika chorob kožních a pohlavních, FN a LF UP Olomouc ³
Published in: Vnitř Lék 2022; 68(5): 285-289
Category: Main Topic
doi: https://doi.org/10.36290/vnl.2022.061

Overview

Systemic scleroderma (SSc) is a systemic immune-mediated connective tissue disease characterized by fibroproductive changes in connective tissue and microvascular disorders. The disease affects the skin, musculoskeletal system and internal organs. It is a disease with a significant rate of morbidity and mortality, significantly worsening the quality of life of patients. Early initiation of therapy is necessary to prevent disease progression. This review article discusses the current possibilities of early diagnosis of systemic scleroderma.

Keywords:

diagnostics – early forms of scleroderma – systemic scleroderma

Sources

1. Assassi S, Del Junco D, Sutter K et al. Clinical and genetic factors predictive of mortality in early systemic sclerosis. Arthritis Rheumatism. 2009;61:1403-1411.

2. Bečvář R, Soukup T, Štork J et al. Doporučení České revmatologické společnosti pro diagnostiku systémové sklerodermie. Česká Revmatologie. 2014;22, č. 2.

3. Gemma Lepri, Silvia Bellando Randone, Marco Matucci Cerinic et al. Early diagnosis of systemic sclerosis, where do we stand today?, Expert Review of Clinical Immunology. 2022, 18:1,1-3. Available from DOI: < https://doi.org/10.1080/1744666X.2022.2015327>

4. Ariane L. Herrick, Fredrick M. Wigley. Raynaud’s phenomenon, Best Practice & Research Clinical Rheumatology. 2020, Volume 34, Issue 1, 1521-6942.

5. Soukup T et al. Systémová sklerodermie v roce 2017. Vnitř Lék 2018; 64(2):146-154.

6. Poudel DR, Jayakumar D, Danve A et al. Determinants of mortality in systemic sclerosis: a focused review. Rheumatology International, 2017;38(10),1847-1858.

7. Horák P, Žurková M, Skoumalová A et al. Rozšiřující se možnosti léčby intersticiálního plicního postižení u systémových onemocnění pojiva. Remedia 2022;32:12-20.

8. Roofeh D, Lescoat A, Khanna D. Treatment for systemic sclerosis‑associated interstitial lung disease. Current Opinion in Rheumatology, 2021; 33(3),240–248. Available from DOI: https:// doi.org/10.1097/bor.0000000000000795

9. Perelas A, Silver RM, Arrossi AV et al. Systemic sclerosis‑associated interstitial lung disease. Lancet Respir Med. 2020; 8(3):304-320. Available from DOI: <https://doi.org/10.1016/S2213-2600(19)30480-1>

10. Shanmugam VK, Steen VD. Renal disease in scleroderma: an update on evaluation, risk stratification, pathogenesis and management. Curr Opin Rheumatol. 2012;24(6):669-676. Available from DOI: <https://doi.org/10.1097/BOR.0b013e3283588dcf>

11. Woodworth TG, Suliman YA., LW, Furst DE, Clements P. Scleroderma renal crisis and renal involvement in systemic sclerosis. Nature Reviews Nephrology. 2016;12(11),678-691. Available from DOI: https://doi.org/10.1038/nrneph.2016.124

12. Adler S, Varisco P, Distler O et al. SAT0508 Ace‑inhibitors in arterial hypertension in ssc patients display a risk factor for scleroderma renal crisis – a eustar analysis. Ann Rheum Dis 2018; 77:1110.

13. Frech TM, Mar D. Gastrointestinal and Hepatic Disease in Systemic Sclerosis. Rheum Dis Clin North Am. 2018;44(1):15-28. Available from DOI: <https://doi.org/10.1016/j.rdc.2017. 09. 002>

14. Morrisroe KB, Nikpour M, Proudman SM. Musculoskeletal Manifestations of Systemic Sclerosis. Rheumatic Disease Clinics of North America, 2015; 41(3),507-518. Available from DOI: <https://doi.org/10.1016/j.rdc.2015. 04. 011>

15. Randone SB, Guiducci S, Cerinic MM. Musculoskeletal involvement in systemic sclerosis. Best Practice & Research Clinical Rheumatology, 2008;22(2), 339-350. Available from DOI: <https://doi.org/10.1016/j.berh.2008. 01. 008 >

16. Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685-1699. Available from DOI: < https://doi.org/10.1016/S0140-6736(17)30933-9>

17. van Den Hoogen F, Khanna D, Fransen J et al. 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European league against rheumatism collaborative initiative. Ann Rheum, DiS. 2013;72(11):1747-1755.

18. Avouac J, Fransen J, Walker U et al. Preliminary criteria for the very early diagnosis of systemic sclerosis: results of a Delphi Consensus Study from EULAR Scleroderma Trials and Research Group. Annals of the Rheumatic Diseases. 2010;70(3),476-481. Available from DOI: <https://doi.org/10.1136/ard.2010.136929>